JMP Securities Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated his 'Market Outperform' rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a price target of $70.
October 09, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals' stock may see positive movement as JMP Securities maintains a 'Market Outperform' rating and a $70 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Market Outperform' rating and a high price target by JMP Securities suggests strong confidence in Mirum Pharmaceuticals' performance, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100